Tempus is a medical technology that aggregates clinical information and provides genetic testing. Eric Lefkofsky started the company in 2015, aiming to offer solutions to the fight against cancer. However, the company is now using its knowledge base to help control Covid-19. Eric Lefkofsky started the company when he realized very little data was available for doctors when treating cancer patients. The CNBC Disruptor 50 ranked Tempus sixth in their 2020 list. The company avails genomic tests to physicians to allow them to make real-time decisions.
Currently, one of the most popular tests searches for more than 600 cancer-related genes. According to businessman and entrepreneur Eric Lefkofsky, the medical technology company Tempus firm collaborates with healthcare centers to aggregate and organize clinical data in electronic health records. The Tempus medical research organization strips off identity from the data to maintain patient anonymity. Medical practitioners then use the data for research to identify and observe any patterns (Chicagobusiness).
Fight Against Covid-19
Eric Lefkofsky felt the company should provide solutions for cancer and help cure various illnesses such as depression, cardiovascular diseases, diabetes, and Covid-19. In April 2020, the company’s Atlanta and Chicago laboratories started providing Covid-19 PCR tests. Under the leadership of Eric Lefkofsky,Tempus’ objective was to increase the testing capacity to 10,000 per day. The firm also began collecting data from the patients to contribute to drug-discovery efforts and treatment.
AI Limitation in Medicine
Artificial intelligence has contributed to the advancement of medicine today. However, as Dr. Jose Morey notes, inadequate data for a new virus limits the efficiency of artificial intelligence.
More on Eric Lefkofsky´s biography and career https://www.capitalgazette.com/ct-elite-street-eric-lefkofsky-glencoe-0528-biz-20170525-story.html